ClinicalTrials.gg
CompletedNCT07542886Updated Aug 10, 2026

A Study to Learn How Different Injector Pens Affect the Study Medicine Called Genotropin (Somatropin) Delivery and Taken up Into the Blood in Healthy Adults

A Phase 1 interventional study of Marketed Genotropin Pen 12 and New Genotropin Injector Pen in Healthy, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this clinical study is to learn about how different injector pens affect:

  • how the study medicine (called Genotropin) is delivered into the body and
  • how the study medicine is taken up into the blood in healthy adults.

The study is seeking participants who are:

  • Aged 18 to 60 years old
  • Male or female who are healthy as determined by medical assessment
  • Body-mass index (BMI) of 16 to 32, and a total body weight more than 45 kg. BMI is a way to estimate a healthy body weight for an adult's height.

Adults in this study will receive study medicine by a shot under the skin. The study medicine will be given using 2 different injector pens which are medical devices that give a shot under the skin. Blood samples will be taken before and after the shots to look for the study medicine. We will compare the amount of study medicine in the blood between shots from the 2 injector pens.

Adults will take part in this study for about 10 weeks including the screening period. They will have to stay at the study clinic for at least 13 days. This includes 2 study periods in total. A follow up phone call will be made 23 to 30 days following the last study period.

02

Conditions studied

  • Healthy

Keywords

  • bioequivalence
  • genotropin
  • adult
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Participants
  • 16 to 32 kg/m2
  • body weight more than 45kg

Exclusion criteria

Exclusion Criteria:

  • Ongoing or past history of significant medical conditions
  • Use of prescription or non prescription medications within 14 days of first study dose
  • Previous exposure to growth hormone
  • History of alcohol abuse, binge drinking or illicit drug use
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Sequence 1

    Single dose of 4 milligrams (mg) subcutaneous genotropin via marketed genotropin pen 12 (Reference) followed by single dose of 4mg subcutaneous genotropin via new genotropin injector pen (Test)

    Device: Marketed Genotropin Pen 12 · Device: New Genotropin Injector Pen · Drug: Genotropin 4mg

  • Experimental
    Sequence 2

    Single dose of 4mg subcutaneous genotropin via new genotropin injector pen (Test) followed by single dose of 4mg subcutaneous genotropin via marketed genotropin pen 12 (Reference)

    Device: Marketed Genotropin Pen 12 · Device: New Genotropin Injector Pen · Drug: Genotropin 4mg

Interventions

  • DeviceMarketed Genotropin Pen 12

    Growth Hormone Delivery Device for use with Somatropin for injection

  • DeviceNew Genotropin Injector Pen

    Growth Hormone Delivery Device for use with Somatropin for injection

  • 4mg subcutaneous

    Also known as: Somatropin

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Somatropin

    AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).

    Time frame: At pre-dose -24, -18, -12, -8, 0 and 1, 2, 3, 4, 6, 8, 10, 12, 16 and 24 hours post-dose on day 1 of each period

  2. Maximum Observed Plasma Concentration (Cmax) for Somatropin

    Time frame: At pre-dose -24, -18, -12, -8, 0 and 1, 2, 3, 4, 6, 8, 10, 12, 16 and 24 hours post-dose on day 1 of each period

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events

    Time frame: From start of study treatment up to 28-35 days after last dose of study treatment (41 days)

  2. Number of Participants With Clinical Laboratory Abnormalities

    Time frame: Up to Day 11

  3. Area under the effect-time curve from 0 to time of last measurable concentration (AUEClast)

    Area under the effect-time curve to the last observed time point of Serum IGF-1

    Time frame: At pre-dose and 6, 12, 24, 48, 72 and 96 hours post-dose on day 1 of each period

  4. Maximum observed effect (Emax)

    Maximum observed effect of Serum IGF-1

    Time frame: At pre-dose and 6, 12, 24, 48, 72 and 96 hours post-dose on day 1 of each period

07

Study locations

1 site
  • Pfizer Clinical Research Unit - Brussels
    Brussels, Bruxelles-capitale, Région de B-1070, Belgium
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2026 to primary completion in Jun 2026, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2026
First posted
Apr 21, 2026
StartActual
Apr 22, 2026
Primary completionActual
Jun 25, 2026
CompletionActual
Jul 24, 2026
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07542886
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 21, 2026
Start date
Apr 22, 2026
Primary completion
Jun 25, 2026
Completion
Jul 24, 2026
Last update
Aug 10, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion